To compare the efficacy of Telmisartan and Ramipril in patients of essential hypertension with type 2 diabetes in controlling the blood pressure and improving lipid profile of the patients.

Abstract

Background: Hypertension is an extremely common comorbid condition in DM, affecting 20-60% patients with DM. As the common denominator of hypertensive diabetic target organ-disease is the vascular tree, the co-existence of hypertension and DM is devastating to cardiovascular and renal system. Lipids stand one of the major contributing factor in cardiovascular morbidity amongst these patients. Many drugs are available in the market to control this, we have studied the efficacy of Telmisartan and Ramipril in improving the lipid profile of these patients. Observation and Results: Group A received Telmisartan while Group B received Ramipril. The baseline lab values of both the groups showed no any statistical difference showing the homogeneity of the groups. Similarly there was no any significant difference between the baseline Lipid profile values of TC, LDL, TG & HDL (All P > 0.05). The reduction in mean SBP & DBP was statistically significant over 12 weeks of therapy in both the groups. But there was no statistical difference inter group wise. It was observed that there was statistically significant difference in mean TC levels, mean LDL levels, when two groups are compared after 12 weeks of therapy. (P value < 0.05). While no significant difference was observed in the values of TG & HDL (P value > 0.05). Conclusion: Our study concludes that there is significant correlation between the use of Telmisartan and Ramipril in lowering the lipids in the patients of Diabetes with Hypertension. Lowering the lipids is very important to prevent any cardiovascular complications, which are one of the major contributing factors to the morbidity and mortality amongst these patients.